Mark L Satz, | |
824 N 11th St, Credentialing, Montevideo, MN 56265-1629 | |
(320) 269-8877 | |
(320) 269-8186 |
Full Name | Mark L Satz |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Location | 824 N 11th St, Montevideo, Minnesota |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487631271 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | 18238 (Minnesota) | Primary |
Entity Name | Ccm Health |
---|---|
Entity Type | Part A Provider - Critical Access Hospital |
Entity Identifiers | NPI Number: 1720086028 PECOS PAC ID: 4284539453 Enrollment ID: O20060504000810 |
News Archive
Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. has initiated the treatment of the first patient in the second of two pivotal studies from the OBI-1's Accur8 clinical trial program.
New technology providing the first view of DNA damage throughout the entire human genome developed by Cardiff University scientists could offer a valuable new insight into the development and treatment of conditions like cancer.
New data from The Kinsey Institute at Indiana University demonstrate that many women think condoms undermine sexual pleasure, but those who use both hormonal contraception and condoms report higher overall sexual satisfaction.
Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Mark L Satz, 824 N 11th St, Credentialing, Montevideo, MN 56265-1629 Ph: (320) 269-8877 | Mark L Satz, 824 N 11th St, Credentialing, Montevideo, MN 56265-1629 Ph: (320) 269-8877 |
News Archive
Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. has initiated the treatment of the first patient in the second of two pivotal studies from the OBI-1's Accur8 clinical trial program.
New technology providing the first view of DNA damage throughout the entire human genome developed by Cardiff University scientists could offer a valuable new insight into the development and treatment of conditions like cancer.
New data from The Kinsey Institute at Indiana University demonstrate that many women think condoms undermine sexual pleasure, but those who use both hormonal contraception and condoms report higher overall sexual satisfaction.
Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.
› Verified 7 days ago